Aim
We aimed to evaluate the effect of gestational diabetes mellitus (GDM) treatment on medium/long‐term outcomes both the mother and offspring.
Methods
We performed a systematic review on randomized clinical trials addressing specific treatment of women with GDM versus usual care and its impact on maternal and offspring outcomes at medium/long‐term. MEDLINE, EMBASE and CENTRAL were searched from inception to 8 October 2021. Outcome variables: maternal (diabetes, metabolic syndrome, 12 secondary); offspring (diabetes, impaired fasting glucose, impaired glucose tolerance, high body mass index, 15 secondary). Risk of bias was assessed with Cochrane tool and aggregation performed with Revman 5.4.
Results
We included five studies (1140 women, 767 offspring) with follow‐up ranging 4–16 years after delivery. GDM treatment likely does not reduce risk of maternal diabetes (RR 1.00; [95% CI 0.82–1.23]) and may not reduce that of metabolic syndrome (RR 0.93; [95% CI 0.71–1.22]). We obtained very uncertain evidence that treatment may increase maternal HDL‐cholesterol. Findings showed that GDM treatment may not have an impact on infants' outcomes (RRs 0.79; [95% CI 0.39–1.69] for impaired fasting glucose; RR 0.91; [95% CI 0.74–1.12] for body mass index >85th centile and 0.89; [95% CI 0.65–1.22] for body mass index >95th centile respectively).
Conclusions
With current evidence is uncertain if specific treatment of women with GDM has an impact on medium/long‐term metabolic outcomes either in the mother or in the offspring. These results add evidence to the recommendation of systematically reevaluating mother and offspring after delivery.
Registration
OSF, DOI 10.17605/OSF.IO/KFN79